Search
Displaying 1–10 of 727 for “retinal diseases”
-
Landing Page
Information for affected individuals and their families about the role of genetic counseling.
-
Eye On the Cure Research News
Funding for the new grants was made possible by Foundation’s strong donor base and philanthropic partners
-
Foundation Fighting Blindness Commits $6.5 Million for New Retinal Disease Research Grants
Press ReleasesNew grants include development of CRISPR/Cas9 gene-editing treatments, new disease models, and a retinal regeneration therapy
-
Foundation Summit Highlights Robust Growth in Commercial Development for Retinal Disease Therapies
Foundation NewsThe Foundation’s Investing in Cures Summit (ICS), held on April 2, 2022, in Half Moon Bay, California, convened 175 researchers, industry executives, and constituents to present and discuss the expanding and accelerating commercial development of emerging therapies for retinal degenerative diseases.
-
Press Releases
The Foundation Fighting Blindness (FFB), the world’s leading private funding source for inherited retinal disease research, announced major awards in two areas: promising research projects in retinal diseases and career development for clinical researchers.
-
Embrace Your Exceptions: A Mantra for Understanding Retinal-Disease Inheritance
Eye On the Cure Research NewsThe complex and elusive nature of these conditions can also extend to the way they are passed down in families, making diagnosis and prognosis quite challenging.
-
Press Releases
Uni-Rare Study will improve clinical understanding of more IRDs and boost development of potential therapies.
-
Getting the Right Diagnosis for a Retinal Disease
Science EducationDefinitive diagnoses for inherited retinal diseases don’t always come easy, even for the patients of the most knowledgeable doctors.
-
Press Releases
The Foundation Fighting Blindness (the Foundation) and CheckedUp have formed a collaborative partnership to deliver patient-friendly diagnostic and disease-management information to people with retinal diseases such as age-related macular degeneration, retinitis pigmentosa, and Stargardt disease during their visits to eye doctors.
-
Industry News
Investigational LUXTURNA has the potential to be both the first pharmacologic treatment for an inherited retinal disease (IRD) and the first gene therapy for a genetic disease in the United States
First adeno-associated viral (AAV) vector investigational candidate to reach this stage of FDA review
Investigational LUXTURNA clinical program includes up to four years of efficacy data, with observation ongoing
.png)
